REG - Feedback PLC - Director/PDMR Shareholding

FeedbackAnnouncement

22/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221222:nRSV5307Ka&default-theme=true

RNS Number : 5307K  Feedback PLC  22 December 2022

Feedback plc

 

Director Dealings

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the frontline clinical
technology company, announces the following Directors' dealings:

 

Rory Shaw, Non Executive Chairman, has subscribed for 22,270 New Ordinary
Shares at a price of 89.8 pence per Ordinary Share.

 

Philipp Prince, Non Executive Director, has subscribed for 4,531 New Ordinary
Shares at a price of 89.9 pence per Ordinary Share.

 

Annemijn Eschauzier, Non Executive Director, has subscribed for 5,440 New
Ordinary Shares at a price of 91.9 pence per Ordinary Share.

 

Details of the Ordinary Shares held by these Directors are detailed in the
table below:

 

 Director/ PDMR       Position                Existing interest in Ordinary Shares  Ordinary Shares purchased  Total beneficial interest in Ordinary Shares  Total interest in Company's issued share capital
 Rory Shaw            Non-Executive Chairman  56,303                                22,270                     78,573                                        0.59%
 Philipp Prince       Non-Executive Director  20,232                                4,531                      24,763                                        0.19%
 Annemijn Eschauzier  Non-Executive Director  -                                     5,440                      5,440                                         0.04%

 

The notification set out below, provides further details of such dealings:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Names                                                        Rory Shaw

                                                                   Philipp Prince

                                                                   Annemijn Eschauzier
 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

                                                                   Non-Executive Director

                                                                   Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Feedback plc

 b)   LEI                                                          213800UGOF2GT2U2RV90

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.50 pence each in Feedback plc

      Identification code                                          GB00BJN59X09

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     89.8p             22,270
                                                                                     89.9p             4,531
                                                                                     91.9p             5,440

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                      21 December 2022

 f)   Place of the transaction                                     XLON

 

Enquiries:

 

 Feedback plc                                    +44 (0) 20 3997 7634

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                            07748 325 236 or 07407 020 470

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for
patients. We design products that enhance clinician access to patient data and
to their colleagues. Our unique approach centres around individual patient
episodes, into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available to
clinicians in multiple settings, in a format that enables them to meaningfully
interact with it, providing flexibility to clinicians and free movement of
patients between provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment.

 

Our products Bleepa and CareLocker work together to deliver unparalleled value
to our customers. Bleepa is our application layer and sits on top of
CareLocker as our data layer. Bleepa is a clinician facing platform that
displays clinical results from a patient's CareLocker at a certified and
regulated quality, that is suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure, auditable chat
interface that links back to the patient medical record. The CareLocker data
storage model is built around the patient. Our vision is one where relevant
clinical data is always available to the patient as well as to any care
setting that they may attend -  a federated data architecture with the
patient as the tenant.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS, the veterinary
market and private healthcare providers and its highly scalable Software as a
Service ("SaaS")-based revenue model is expected to provide increasing levels
of visibility as the Company grows its customer base.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPGWUPUPPGMG